Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (265)	1/21/1999 1:09:00 AM
From: Lel H	Respond to of 626

The information about Iloperidone's phase III trial has been known officially since August, and even before that I had received some details about the trial from Bob Farrell. The Novartis announcement really wasn't new, expect that it gave Iloperidone a trademark name, provided more details about the clinical trial design, and gave Titan a little more visibility. With respect to study sites, I don't know what to read into it. With at least one other company that I follow, I have noticed that they tend to start clinical trials in Europe first and in the US second. Perhaps the regulatory hurdles in Europe are lower than those in the US.

To: John Metcalf who wrote (265)	1/21/1999 8:24:00 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 626

I do not believe that it is correct to assume that only this 600pt study will be US based, and that all others will be done elsewhere. There is going to be a series of Phase IIIs, in various subtypes of schizophrenia and comparing iloperidone head to head with other drugs; Risperdal, Clozaril, Zyprexa. This first is in the US, others will be as well. You are correct that Novartis is not just seeking to show advantage re: agranulocytosis, they have the larger task of matching Zyprexa, which approached $500 million in sales its first year. NeuroInvestment (www.neuroinvestment.com)